EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53

Alexa J Siddon, Olga K Weinberg

Clinics in Laboratory Medicine · 2023

DOI: 10.1016/j.cll.2023.07.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinics in Laboratory Medicine, 2023. Verfasst von Alexa J Siddon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, PO Box 208035, New Haven, CT 06520, USA; Department of Pathology, Yale …. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The genetic underpinnings of myeloid neoplasms are becoming increasingly well understood. The accessibility to sequencing technology, in particular next-generation sequencing (NGS), has highlighted the importance of gene mutations in myelodysplastic syndromes (MDS) in conjunction with traditional cytogenetics. With the relatively recent influx of molecular information to complement known cytogenetic abnormalities, the diagnosis, classification, and prognosis of MDS and acute myeloid leukemia (AML) have been increasingly refined, which has also led to therapeutic advancements. It has been shown that TP53 mutations have a significant impact in cases of MDS, as well as AML, and have led to TP53-defined myeloid disease. TP53 mutations are also now incorporated into prognostic scoring systems, as patients have been shown to have aggressive disease and poor outcomes. With the increased understanding of the importance of TP53 disruption in myeloid neoplasia, it is likely that the critical role of TP53 will continue to be highlighted by an individual's disease classification and personalized therapeutic management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansMutationChromosome AberrationsPrognosisTumor Suppressor Protein p53

Stichwörter der Autor:innen

CytogeneticsMutationsMyelodysplasiaMyelodysplastic syndromesNext generation sequencingPrognosisTP53

Substanzen

TP53 protein, humanTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, PO Box 208035, New Haven, CT 06520, USA; Department of Pathology, Yale School of Medicine, 330 Cedar Street, PO Box 208035, New Haven, CT 065…
  • Department of Pathology, University of Texas Southwestern Medical Center, BioCenter, 2230 Inwood Road, EB03.220G, Dallas, TX 75235, USA.

Zitieren

APA

Siddon, A. J., & Weinberg, O. K. (2023). Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics in Laboratory Medicine. https://doi.org/10.1016/j.cll.2023.07.004

Vancouver

Siddon AJ, Weinberg OK. Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53. Clinics in Laboratory Medicine. 2023. doi:10.1016/j.cll.2023.07.004

BibTeX
@article{Siddon2023,
  author = {Siddon, Alexa J and Weinberg, Olga K},
  title = {Diagnosis and Classification of Myelodysplastic Syndromes with Mutated TP53},
  journal = {Clinics in Laboratory Medicine},
  year = {2023},
  doi = {10.1016/j.cll.2023.07.004}
}
Kostenlos starten →